Back
Molybdenum-99 market seen reaching $8.33 billion by 2035, report says

Molybdenum-99 market seen reaching $8.33 billion by 2035, report says

Healthcare Foresights projects the market will rise from $5.17 billion in 2025 to $5.40 billion in 2026, supported by demand for SPECT imaging and broader use of nuclear medicine diagnostics.

Fact Check
The GlobeNewswire press release ('[Latest] Global Molybdenum 99 Market Size/Share Worth USD 8.33 Billion by 2035') is the primary source for this claim and matches every specific figure exactly: USD 5.17 billion in 2025, USD 5.40 billion in 2026, USD 8.33 billion by 2035, 4.89% CAGR, and the stated drivers (SPECT imaging and nuclear medicine diagnostics). The claim is an accurate report of what the source published. The underlying numbers are vendor forecast projections rather than independently audited facts, but the claim correctly attributes them to the report, so it is accurate as stated.
    Reference: 1
Summary

Healthcare Foresights has published a report projecting the global molybdenum-99 market to grow from USD 5.17 billion in 2025 to USD 5.40 billion in 2026 and to about USD 8.33 billion by 2035, implying a 4.89% compound annual growth rate over 2026 to 2035. The study links growth to rising use of nuclear medicine imaging, especially SPECT procedures, and to higher demand for early diagnosis of cardiovascular disease, cancer and neurological disorders. Reactor-based production is identified as the leading production method because of its large-scale output and established supply chains, while accelerator-based production is described as the fastest-growing segment as the industry looks to diversify isotope supply beyond traditional reactors. Diagnostic imaging using SPECT is the dominant application, with oncology diagnostics and cardiology imaging among the fastest-growing uses, and hospitals are the largest end-use segment because they house nuclear medicine departments and radiology infrastructure. Asia Pacific is expected to be the fastest-growing regional market, supported by healthcare infrastructure spending and adoption of advanced diagnostics, while North America remains a significant market and Europe is seen posting steady growth. Companies named in the report include NRG, Curium, NTP Radioisotopes, ANSTO, NorthStar Medical Radioisotopes, SHINE Technologies, IRE (Institut des Radioéléments / IRE-Elit), Lantheus Medical Imaging, Eckert & Ziegler and Rosatom State Atomic Energy Corporation.

Terms & Concepts
  • Molybdenum-99: A medical isotope used to produce technetium-99m, which is widely used in nuclear medicine imaging.
  • SPECT imaging: Single-photon emission computed tomography, a nuclear imaging technique used to assess how organs and tissues function.
  • LEU targets: Low-enriched uranium targets used in isotope production as an alternative aligned with non-proliferation goals.